FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Conference Call May 6, 2024 5:00 PM ET

Company Participants

David DeLucia - VP, Corporate FP&A and IR
Thane Wettig - CEO
Deyaa Adib - CMO
Juan Graham - CFO
Chris Chung - SVP, China Operations

Conference Call Participants

Andy Hsieh - William Blair
Paul Choi - Goldman Sachs

Operator

Good day and thank you for standing by. Welcome to the FibroGen's First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, David DeLucia, Vice President, Investor Relations.

David DeLucia

Good afternoon everyone. Thank you for joining today to discuss our first quarter 2024 financial and business results. I'm David DeLucia, Vice President of Corporate FP&A and Investor Relations at FibroGen.

Joining me on today's call are Thane Wettig, our Chief Executive Officer; Dr. Deyaa Adib, our Chief Medical Officer; Juan Graham, our Chief Financial Officer; Dr. John Hunter, our Chief Scientific Officer; and Chris Chung, our Senior Vice President of China Operations. Following our prepared remarks, we will open the call to your questions.

I would like to remind you that remarks made on today's call include forward-looking statements about FibroGen. Such statements may include, but are not limited to, our collaborations with AstraZeneca and Astellas; financial guidance; the initiation, enrollment, design, conduct, and results of clinical trials; our regulatory strategies and potential regulatory results; our research and development activities; commercial results and results of operations; risks related to our business; and certain other business matters.

Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to